Meta-analysis of ciltacabtagene autoleucel versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma

  • Luciano J. Costa (Creator)
  • Parameswaran Hari (Creator)
  • Jesus G. Berdeja (Creator)
  • Valerio De Stefano (Creator)
  • Francesca Gay (Creator)
  • Becky Hooper (Creator)
  • Meaghan Bartlett (Creator)
  • Anja Haltner (Creator)
  • Emily Rosta (Creator)
  • Shaji Kumar (Creator)
  • Thomas Martin (Creator)
  • Maria-Victoria Mateos (Creator)
  • Philippe Moreau (Creator)
  • Saad Z. Usmani (Creator)
  • Yunsi Olyslager (Creator)
  • Jordan M. Schecter (Creator)
  • Tito Roccia (Creator)
  • Ashraf Garrett (Creator)
  • Sam Lee (Creator)
  • Tonia Nesheiwat (Creator)
  • Lida Pacaud (Creator)
  • Changwei Zhou (Creator)
  • Imtiaz A. Samjoo (Creator)
  • Yi Lin (Creator)
  • Joris Diels (Creator)
  • Satish Valluri (Creator)
  • Katja Weisel (Creator)

Dataset

Description

<b>Objective:</b> In the absence of head-to-head trials, indirect treatment comparisons (ITCs) between ciltacabtagene autoleucel (cilta-cel; in CARTITUDE-1) and treatments used in real-world clinical practice (physician’s choice of treatment [PCT]), were previously conducted. We conducted multiple meta-analyses using available ITC data to consolidate the effectiveness of cilta-cel versus PCT for patients with triple-class exposed relapsed or refractory multiple myeloma (RRMM). <b>Methods:</b> Five ITCs were assessed for similarity to ensure robust comparisons using meta-analysis. Effectiveness outcomes were overall survival (OS), progression-free survival (PFS), time to next treatment (TTNT), and overall response rate (ORR). A robust variance estimator was used to account for the use of CARTITUDE-1 in each pairwise ITC. Analyses were conducted in both treated and enrolled populations of CARTITUDE-1. <b>Results:</b> Four ITCs were combined for evaluation of OS. Results were statistically significantly in favor of cilta-cel versus PCT in treated patients (hazard ratio [HR]: 0.24, 95% confidence interval [CI]: 0.22 to 0.26). Three ITCs were combined for evaluation of PFS and TTNT. Cilta-cel reduced the risk of progression and receiving a subsequent treatment by 80% (HR: 0.20 [95% CI: 0.06, 0.70]) and 83% (HR: 0.17 [95% CI: 0.12, 0.26]), respectively. Three ITCs were combined for evaluation of ORR. Cilta-cel increased the odds of achieving an overall response by 86-times versus PCT in treated patients. Findings were consistent in the enrolled populations and across sensitivity analyses. <b>Conclusions:</b> Evaluating multiple indirect comparisons, cilta-cel demonstrated a significantly superior advantage over PCT, highlighting its effectiveness as a therapy in patients with triple-class exposed RRMM.
Dati resi disponibili2022
EditoreTaylor & Francis

Cita questo